Latest News

• share
• favorite_border

ALEXANDRIA, VA – Data from a new study presented this week at The Liver Meeting Digital Experience® – held by the American Association for the Study of Liver Diseases – found that COVID-19 coagulation impairment, driven in part by endothelial Factor VIII, is associated with liver injury in infected patients. The study’s findings also show that IL-6 trans-signaling, which may play a role in COVID-19 development, results in prothrombotic liver sinusoidal endothelial cells (LSECs) that may mediate the liver injury via elevated Factor VIII and activation of coagulation in the liver microvasculature.

• share
• favorite_border

Data from a new study presented this week at The Liver Meeting Digital Experience® – held by the American Association for the Study of Liver Diseases – found that using neural networks, a type of machine learning algorithm, is a more accurate model for predicting waitlist mortality in liver transplantation, outperforming the older model for end-stage liver disease (MELD) scoring. This advancement could lead to the development of more equitable organ allocation systems and even reduce liver transplant waitlist death rates for patients.

• share
• favorite_border

Data from a new study presented this week at The Liver Meeting Digital Experience® – held by the American Association for the Study of Liver Diseases – found that in 2019, more than 500,000 persons died of hepatitis B virus infection, highlighting the urgent need for universal HBV vaccination of children beginning at birth, and scaling up testing and access to care and treatment before people with the virus develop life-threatening liver cirrhosis or liver cancer.

• share
• favorite_border

Data from a new study presented this week at The Liver Meeting Digital Experience® – held by the American Association for the Study of Liver Diseases – found that while neighborhood socioeconomic deprivation is associated with worse adverse long-term outcomes after liver transplant in children, improving center-specific practices can mitigate these effects for young at-risk patients.

• share
• favorite_border

The American Association for the Study of Liver Diseases (AASLD) Foundation, the largest private supporter of liver disease research and training in the United States, today announced its combined investment of over $2.2 million in Research and Career Development Awards, Abstract Awards, and its Emerging Liver Scholars (ELS) Program.

• share
• favorite_border

The American Association for the Study of Liver Disease (AASLD) has released a clinical insight document for clinicians and frontline healthcare providers who are treating patients with liver disease during the COVID-19 pandemic. The document, which cites recent studies conducted in China, assesses how hepatologists and liver transplant physicians/surgeons and their patients may be affected by the COVID-19 virus (also known as SARS-CoV-2) and provides continued guidance on clinical approaches to disease management.

• share
• favorite_border

HCVguidelines.org — a website developed by the American Association for the Study of Liver Diseases and the Infectious Diseases Society of America to provide up-to-date guidance on the management of hepatitis C — was recently revised to reflect important developments in the identification and management of chronic hepatitis C (HCV)

• share
• favorite_border

The American Association for the Study of Liver Diseases (AASLD) has appointed Matthew R. D’Uva, FASAE, CAE, as its new chief executive officer, effective January 21, 2020.

• share
• favorite_border

Data from a new study presented this week at The Liver Meeting® – held by the American Association for the Study of Liver Diseases – found that kratom, a popular and widely available product, may cause liver toxicity and severe liver injury.

• share
• favorite_border

Data from a new study presented this week at The Liver Meeting® – held by the American Association for the Study of Liver Diseases – found fewer new cases of hepatitis C infection (commonly called HCV), despite very high rates of other sexually-transmitted infections, in HIV-negative men who have sex with men who take pre-exposure prophylaxis (PrEP) treatments.

• share
• favorite_border

Data from a new study presented this week at The Liver Meeting® – held by the American Association for the Study of Liver Diseases – found that cirrhosis patients in the U.S. have substantial financial burden

• share
• favorite_border

Four societies focused on liver disease research and treatment announced a global call-to-action initiative to simplify hepatitis C testing and treatment.

• share
• favorite_border

Data from a new study presented this week at The Liver Meeting® – held by the American Association for the Study of Liver Diseases – found that a substantial burden of hepatocellular carcinoma (HCC) and cirrhosis-related deaths may be prevented by lifestyle modifications to diet, alcohol use and exercise.

• share
• favorite_border

Data from a new study presented this week at The Liver Meeting® – held by the American Association for the Study of Liver Diseases – found that hepatitis C virus-related hepatocellular carcinoma (HCC) patients who achieved sustained virologic response (SVR) – denoting an undetectable level of HCV virus - with any oral direct-acting antiviral (DAA) had over 60-70 percent improvement in five-year survival.

• share
• favorite_border

Data from a new study presented this week at The Liver Meeting® – held by the American Association for the Study of Liver Diseases – found that obese individuals with nonalcoholic fatty liver disease (NAFLD) were less likely to achieve a medically recommended five percent loss of body weight at three months

• share
• favorite_border

Data from a new study presented this week at The Liver Meeting® – held by the American Association for the Study of Liver Diseases – found that a machine-learning tool could successfully predict the risk of having non-alcoholic steatohepatitis (NASH) among patients with co-existing diseases.

• share
• favorite_border

Data from a new study presented this week at The Liver Meeting® – held by the American Association for the Study of Liver Diseases and funded by the AASLD Foundation

• share
• favorite_border

Data from a new study presented this week at The Liver Meeting® – held by the American Association for the Study of Liver Diseases – found that combination therapy with direct-acting antivirals (DAAs) and ezetimibe

• share
• favorite_border

The American Association for the Study of Liver Diseases Foundation, the largest private supporter of liver disease research and training in the United States, today announced its investment of $3.42 million in Research and Career Development Awards granted to 29 researchers and clinicians to conduct innovative liver disease research and seek advanced hepatology training.